HOME > COMMENTARY
COMMENTARY
-
COMMENTARY/Permitting MSs to Take MR Cert. Exam Offers New Business Opportunity to Wholesalers
August 3, 2009
-
COMMENTARY/Fair Profits Are Essential to Spread Regenerative Medicine
August 3, 2009
-
Hitech Drugs Open the Window to the Future- With Special Focus on Development and Marketing -(1)
July 20, 2009
-
Hitech Drugs Open the Window to the Future- With Special Focus on Development and Marketing -(2)
July 20, 2009
-
COMMENTARY/Global Pharmas Enhance Their Presence in Japan
July 13, 2009
-
COMMENTARY/Clinical Applications of ADCs Coming Closer to Reality
June 29, 2009
-
COMMENTARY/Additional Price Cuts for Long-listed Original Drugs
June 29, 2009
-
SURVEY/RLS Takes Almost Four Years before Being Diagnosed
June 22, 2009
-
COMMENTARY/JSHP to Promote Use of Generics
June 8, 2009
-
COMMENTARY/Combination Drugs Becoming a "Boom"
June 1, 2009
-
COMMENTARY/Clearer Criteria Needed for Patent Period Restoration
May 4, 2009
-
COMMENTARY/Why Does the Use of Generics Not Increase?
April 27, 2009
-
EMTs Allowed to Administer Epipen
April 27, 2009
-
COMMENTARY/Medway Data Falsification to Make Blood Product Self-Sufficiency Difficult
April 20, 2009
-
The First Round Results of GE Amlodipine (2)- Making No Surprise Moves Leads to Success -
April 6, 2009
-
COMMENTARY/Worst Scenario Coming True due to Heated Competition among Wholesalers
March 23, 2009
-
Unexpected Demand for ActHIB Causes Shortage of Supply
March 16, 2009
-
COMMENTARY/Aggressive Overseas Investments Affect Business of Top-4 Pharmas
February 23, 2009
-
COMMENTARY/National Consensus Needed to Balance Soaring Costs of New Drugs against Their Benefits
February 16, 2009
-
Majority of People Have Misconceptions about Antibacterials: Pfizer Survey
February 9, 2009
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
